Two Young Chefs Have Passed the Japanese Cuisine Certification Exam (Organized by JCDC) and Have Newly Acquired Gold Certification!
21.3.2025 15:00:00 CET | Business Wire | Press release
Based on the “Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries” established by the Ministry of Agriculture, Forestry and Fisheries (MAFF) of Japan
The Japanese Cuisine and Dietary Culture Development Committee (JCDC) (Location: Minato-ku, Tokyo; Representative: Yoshihiro Murata; Website: https://en.jcdc.tokyo/), which supports and promotes the spread of Japanese food overseas, held a certification exam for foreign chefs in Kyoto. This certification exam is based on the “Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries” (enacted on April 1, 2016 / revised on April 1, 2024) established by the Ministry of Agriculture, Forestry and Fisheries (MAFF) of Japan. In this examination, two people from Vietnam, Le Minh Tien and Pham Duc Duy, successfully obtained Gold certification. In addition, the two foreign chefs who came to Japan to participate in the Kyoto final of the “Road to Japanese Culinary Arts Award 2024-2025” hosted by the Japanese Culinary Academy were also certified as Silver.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316366476/en/
Certification Badges
Of the three types of certification (bronze, silver and gold), the gold certification, which has the most stringent requirements and highest level, has only been obtained by 23 people worldwide as of September 2024. The two new gold certification holders (who have graduated from a training school for Licensed Cooks in Japan and have at least five years of work experience at a Japanese restaurant in Japan) are the first gold certification holders since the guidelines were revised. It is hoped that the certified holders under this system will continue to play an active role in the promotion and development of Japanese cuisine.
Date and time:
Wednesday, March 12, 10:15 - 13:15
Venue:
Taiwa Gakuen Kyoto Culinary Art College (4-5 Uzumasa Yasui Nishizawa-cho, Ukyo-ku, Kyoto City)
Judges:
Masahiro Nakata (Director of the Taiwa Gakuen Hospitality Industry Promotion Center, Director of the Japanese Culinary Academy)
Motoi Kurisu (Owner/Chef of “Arashiyama Kumahiko”, Director of the Japanese Culinary Academy)
Exam content:
A: Cooking a "Shokado bento" and soup which condenses the essence of kaiseki cuisine (Gold)
B: Cooking “Ichu-jyu, Go-sai" (one soup and five dishes) using the five basic techniques of Japanese cuisine (Silver)
[About the Certification of Cooking Skills for Japanese Cuisine in Foreign Countries]
In order to appropriately and effectively convey the appeal of Japanese food and food culture, as well as Japanese agricultural, forestry and marine products and foods, to people overseas, private organizations, etc. certify foreign chefs of Japanese cuisine who have reached a certain level of knowledge and cooking skills related to Japanese cuisine as Gold, Silver or Bronze, based on the guidelines set by the Ministry of Agriculture, Forestry and Fisheries of Japan (MAFF).
- Certification of Cooking Skills for Japanese Cuisine in Foreign Countries (MAFF HP)
https://www.maff.go.jp/j/shokusan/syokubun/tyori.html
https://www.maff.go.jp/j/shokusan/syokubun/pdf/chori_s_e.pdf
- Introduction of previous certification holders (Gold and Silver) ("Taste of Japan" website)
https://japan-food.jetro.go.jp/en/supporter/certification/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316366476/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom